Skip to main content
NCBI home page
Other Publishers logoLink to Other Publishers
. 2020 Jan 31;31(3):442. doi: 10.1016/j.annonc.2020.01.002

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Ann Oncol 2019; 30: 1992–2003

NW Clarke 1,∗, A Ali 2, FC Ingleby 3,4, A Hoyle 1, CL Amos 3, G Attard 5, CD Brawley 3, J Calvert 3, S Chowdhury 6, A Cook 3, W Cross 7, DP Dearnaley 8, H Douis 9, D Gilbert 3, S Gillessen 10, RJ Jones 11, RE Langley 3, A MacNair 3, Z Malik 12, MD Mason 13, D Matheson 14, R Millman 3, CC Parker 8,15, AWS Ritchie 3, H Rush 3, JM Russell 16, J Brown 17, S Beesley 18, A Birtle 19, L Capaldi 20, J Gale 21, S Gibbs 22, A Lydon 23, A Nikapota 24, A Omlin 25, JM O’Sullivan 26, O Parikh 27, A Protheroe 28, S Rudman 6, NN Srihari 29, M Simms 30, JS Tanguay 31, S Tolan 12, J Wagstaff 32, J Wallace 11, J Wylie 33, A Zarkar 34, MR Sydes 3, MKB Parmar 3, ND James 35; the STAMPEDE investigators
PMCID: PMC8929236  PMID: 32067690

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.

RESOURCES